JP2010534684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534684A5 JP2010534684A5 JP2010518431A JP2010518431A JP2010534684A5 JP 2010534684 A5 JP2010534684 A5 JP 2010534684A5 JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010534684 A5 JP2010534684 A5 JP 2010534684A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- amino acid
- acid sequence
- cationic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 125000002091 cationic group Chemical group 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95205907P | 2007-07-26 | 2007-07-26 | |
| US60/952,059 | 2007-07-26 | ||
| PCT/US2008/071350 WO2009015385A1 (en) | 2007-07-26 | 2008-07-28 | Antimicrobial peptide, compositions , and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013222846A Division JP5965884B2 (ja) | 2007-07-26 | 2013-10-28 | 抗菌ペプチド、組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534684A JP2010534684A (ja) | 2010-11-11 |
| JP2010534684A5 true JP2010534684A5 (enExample) | 2011-06-02 |
| JP5401457B2 JP5401457B2 (ja) | 2014-01-29 |
Family
ID=40281862
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518431A Expired - Fee Related JP5401457B2 (ja) | 2007-07-26 | 2008-07-28 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2013222846A Expired - Fee Related JP5965884B2 (ja) | 2007-07-26 | 2013-10-28 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2016132290A Pending JP2017002057A (ja) | 2007-07-26 | 2016-07-04 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2018153719A Active JP6722241B2 (ja) | 2007-07-26 | 2018-08-17 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2020105975A Pending JP2020169190A (ja) | 2007-07-26 | 2020-06-19 | 抗菌ペプチド、組成物及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013222846A Expired - Fee Related JP5965884B2 (ja) | 2007-07-26 | 2013-10-28 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2016132290A Pending JP2017002057A (ja) | 2007-07-26 | 2016-07-04 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2018153719A Active JP6722241B2 (ja) | 2007-07-26 | 2018-08-17 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2020105975A Pending JP2020169190A (ja) | 2007-07-26 | 2020-06-19 | 抗菌ペプチド、組成物及びその使用方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8623811B2 (enExample) |
| EP (3) | EP3741380A1 (enExample) |
| JP (5) | JP5401457B2 (enExample) |
| KR (4) | KR101717275B1 (enExample) |
| CN (2) | CN101842107B (enExample) |
| AU (1) | AU2008278593B2 (enExample) |
| BR (3) | BR122019000258B1 (enExample) |
| CA (1) | CA2694046C (enExample) |
| CO (1) | CO6260098A2 (enExample) |
| CR (1) | CR11239A (enExample) |
| CY (2) | CY1118503T1 (enExample) |
| DK (2) | DK2178549T3 (enExample) |
| ES (2) | ES2805225T3 (enExample) |
| HR (1) | HRP20161722T1 (enExample) |
| HU (1) | HUE031136T2 (enExample) |
| IL (3) | IL203173A (enExample) |
| LT (1) | LT2178549T (enExample) |
| MX (1) | MX2010000916A (enExample) |
| NZ (1) | NZ582459A (enExample) |
| PL (1) | PL2178549T3 (enExample) |
| PT (2) | PT3120862T (enExample) |
| SG (1) | SG188128A1 (enExample) |
| SI (1) | SI2178549T1 (enExample) |
| WO (1) | WO2009015385A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598159A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
| ES2805225T3 (es) * | 2007-07-26 | 2021-02-11 | Revance Therapeutics Inc | Péptidos antimicrobianos y composiciones de los mismos |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| EP3031825B1 (en) | 2008-03-14 | 2019-07-24 | Allergan, Inc. | Immuno-based botulinum toxin serotype a activity assays |
| EP3332805B1 (en) * | 2008-12-31 | 2022-02-23 | ReVance Therapeutics, Inc. | Injectable botulinum toxin formulations |
| US20120148562A1 (en) * | 2009-04-01 | 2012-06-14 | Revance Therapeutics, Inc. | Methods and compositions for treating skin conditions associated with vascular hyper-reactivity |
| AU2010259986B2 (en) | 2009-06-10 | 2015-04-02 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| AU2010265888A1 (en) | 2009-06-25 | 2012-01-19 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
| US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
| US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
| FR2997304B1 (fr) | 2012-10-26 | 2017-07-07 | Isp Investments Inc | Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens |
| MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
| US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| RU2724545C2 (ru) | 2015-09-17 | 2020-06-23 | Контрафект Корпорейшн | Полипептиды лизина, активные против грамотрицательных бактерий |
| US10105381B2 (en) * | 2016-05-23 | 2018-10-23 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US10144767B2 (en) * | 2016-08-18 | 2018-12-04 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and coatings |
| BR112019010131A2 (pt) * | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
| US12161703B2 (en) | 2017-08-28 | 2024-12-10 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| CN107556374B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用 |
| CN107353334B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用 |
| JP7266202B2 (ja) * | 2018-02-19 | 2023-04-28 | 株式会社ファンケル | 化粧料及び抗炎症剤 |
| NZ793134A (en) * | 2020-04-08 | 2025-10-31 | Amicrobe Inc | Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections |
| WO2025059665A1 (en) | 2023-09-15 | 2025-03-20 | Revance Therapeutics, Inc. | Serial treatment with botulinum toxin for cervical dystonia |
| WO2025064729A1 (en) | 2023-09-19 | 2025-03-27 | Revance Therapeutics, Inc. | Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance |
| WO2025072381A1 (en) | 2023-09-25 | 2025-04-03 | Revance Therapeutics, Inc. | Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| AU4037793A (en) | 1992-04-23 | 1993-11-29 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
| CA2135642C (en) | 1992-08-21 | 1999-12-14 | James G. Barsoum | Tat-derived transport polypeptides |
| CA2152373C (en) * | 1993-10-22 | 1998-12-15 | Michael Twist (Deceased) | Treatment of cytomegalovirus infection |
| EP1600163B1 (en) | 1993-12-28 | 2010-02-17 | Allergan, Inc. | Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle |
| US6232295B1 (en) | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| AU6940796A (en) * | 1995-08-23 | 1997-03-19 | University Of British Columbia, The | Antimicrobial cationic peptides and methods of screening for the same |
| US6043218A (en) * | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
| GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| AU1818299A (en) * | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
| JP2002508187A (ja) * | 1997-12-12 | 2002-03-19 | オニックス ファーマシューティカルズ，インコーポレイティド | Ｐ５３＋新生細胞の選択的殺死及び診断 |
| WO2000024419A1 (en) | 1998-10-27 | 2000-05-04 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
| JP2002531113A (ja) | 1998-12-10 | 2002-09-24 | ワシントン大学 | 蛋白質の形質導入システムおよびその使用法 |
| JP2002533379A (ja) | 1998-12-23 | 2002-10-08 | イデア アクチェンゲゼルシャフト | 生体内における局所的に非侵襲性である用途のための改善された製剤 |
| US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
| US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
| US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
| AU2001284665B2 (en) * | 2000-07-21 | 2006-06-08 | Revance Therapeutics, Inc. | Multi-component Biological Transport Systems |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7585834B2 (en) | 2001-02-16 | 2009-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Transporters comprising spaced arginine moieties |
| JP2004536585A (ja) * | 2001-05-09 | 2004-12-09 | エール・ユニバーシティ | トル／インターロイキン−１受容体アダプタータンパク質（ｔｉｒａｐ） |
| US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| CA2469336C (en) * | 2001-12-11 | 2013-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
| WO2003072049A2 (en) | 2002-02-21 | 2003-09-04 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
| US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| JP4154218B2 (ja) * | 2002-11-27 | 2008-09-24 | 寛紀 高麗 | 新規抗菌性ポリペプチドとその利用 |
| IL153557A0 (en) * | 2002-12-19 | 2003-07-06 | Yitzchak Hillman | Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases |
| WO2004056307A2 (en) * | 2002-12-19 | 2004-07-08 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
| EP1594969B1 (en) * | 2003-02-01 | 2015-05-20 | Janssen Sciences Ireland UC | Active immunization to generate antibodies to soluble a-beta |
| US7482016B2 (en) * | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| MXPA06002828A (es) * | 2003-09-12 | 2006-06-23 | Univ British Columbia | Efectores de determinacion de inmunidad innata. |
| JP2005120050A (ja) * | 2003-10-20 | 2005-05-12 | Toagosei Co Ltd | 新規抗菌性ペプチドとその利用 |
| EP2656859B1 (en) * | 2004-03-03 | 2015-10-21 | ReVance Therapeutics, Inc. | Topical application and transdermal delivery of botulinum toxins |
| KR101284710B1 (ko) | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
| DK1778720T3 (da) * | 2004-08-18 | 2010-11-29 | Novabiotics Ltd | Antimikrobielle peptider omfattende et arginin- og/eller lysinholdigt motiv |
| WO2006050611A1 (en) | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
| EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| EP1661912A1 (en) | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| JP2006238751A (ja) * | 2005-03-02 | 2006-09-14 | Toagosei Co Ltd | ベロ毒素結合性を有する抗菌ペプチド及びその利用 |
| US20090247464A1 (en) | 2005-03-03 | 2009-10-01 | Revance Therapeutics, Inc. | Compositions and Methods for Topical Application and Transdermal Delivery of an Oligopeptide |
| CA2599017C (en) | 2005-03-03 | 2014-08-12 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| BRPI0608951A2 (pt) | 2005-03-30 | 2010-02-17 | Revance Therapeutics Inc | composições e método para o tratamento de acne |
| CA2629499A1 (en) | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| WO2008082889A2 (en) | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat |
| NZ598159A (en) | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
| ES2805225T3 (es) * | 2007-07-26 | 2021-02-11 | Revance Therapeutics Inc | Péptidos antimicrobianos y composiciones de los mismos |
| EP3332805B1 (en) * | 2008-12-31 | 2022-02-23 | ReVance Therapeutics, Inc. | Injectable botulinum toxin formulations |
-
2008
- 2008-07-28 ES ES16184094T patent/ES2805225T3/es active Active
- 2008-07-28 KR KR1020157019647A patent/KR101717275B1/ko active Active
- 2008-07-28 EP EP20166266.5A patent/EP3741380A1/en active Pending
- 2008-07-28 HR HRP20161722TT patent/HRP20161722T1/hr unknown
- 2008-07-28 LT LTEP08826608.5T patent/LT2178549T/lt unknown
- 2008-07-28 MX MX2010000916A patent/MX2010000916A/es active IP Right Grant
- 2008-07-28 KR KR1020187007958A patent/KR102088949B1/ko active Active
- 2008-07-28 BR BR122019000258-4A patent/BR122019000258B1/pt active IP Right Grant
- 2008-07-28 KR KR1020177002763A patent/KR20170016031A/ko not_active Ceased
- 2008-07-28 CA CA2694046A patent/CA2694046C/en active Active
- 2008-07-28 DK DK08826608.5T patent/DK2178549T3/en active
- 2008-07-28 KR KR1020107003133A patent/KR101722038B1/ko active Active
- 2008-07-28 CN CN200880100641.7A patent/CN101842107B/zh active Active
- 2008-07-28 PL PL08826608T patent/PL2178549T3/pl unknown
- 2008-07-28 SG SG2013009832A patent/SG188128A1/en unknown
- 2008-07-28 EP EP08826608.5A patent/EP2178549B1/en active Active
- 2008-07-28 NZ NZ582459A patent/NZ582459A/en unknown
- 2008-07-28 EP EP16184094.7A patent/EP3120862B1/en active Active
- 2008-07-28 WO PCT/US2008/071350 patent/WO2009015385A1/en not_active Ceased
- 2008-07-28 ES ES08826608.5T patent/ES2609914T3/es active Active
- 2008-07-28 BR BR122019000266-5A patent/BR122019000266B1/pt active IP Right Grant
- 2008-07-28 JP JP2010518431A patent/JP5401457B2/ja not_active Expired - Fee Related
- 2008-07-28 CN CN201210375756.5A patent/CN102872447B/zh active Active
- 2008-07-28 AU AU2008278593A patent/AU2008278593B2/en active Active
- 2008-07-28 US US12/669,705 patent/US8623811B2/en active Active
- 2008-07-28 PT PT161840947T patent/PT3120862T/pt unknown
- 2008-07-28 HU HUE08826608A patent/HUE031136T2/en unknown
- 2008-07-28 SI SI200831732T patent/SI2178549T1/sl unknown
- 2008-07-28 BR BRPI0813627-0A patent/BRPI0813627B1/pt active IP Right Grant
- 2008-07-28 DK DK16184094.7T patent/DK3120862T3/da active
- 2008-07-28 PT PT88266085T patent/PT2178549T/pt unknown
-
2010
- 2010-01-06 IL IL203173A patent/IL203173A/en active IP Right Grant
- 2010-01-27 CR CR11239A patent/CR11239A/es not_active Application Discontinuation
- 2010-02-26 CO CO10023449A patent/CO6260098A2/es not_active Application Discontinuation
-
2012
- 2012-12-20 IL IL223784A patent/IL223784A/en active IP Right Grant
- 2012-12-20 IL IL223785A patent/IL223785A/en active IP Right Grant
-
2013
- 2013-10-28 JP JP2013222846A patent/JP5965884B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-04 JP JP2016132290A patent/JP2017002057A/ja active Pending
- 2016-12-14 CY CY20161101296T patent/CY1118503T1/el unknown
-
2018
- 2018-08-17 JP JP2018153719A patent/JP6722241B2/ja active Active
-
2020
- 2020-06-19 JP JP2020105975A patent/JP2020169190A/ja active Pending
- 2020-07-27 CY CY20201100692T patent/CY1123176T1/el unknown